| Followers | 879 |
| Posts | 304355 |
| Boards Moderated | 5 |
| Alias Born | 06/09/2006 |
Thursday, June 27, 2019 2:16:46 PM
You can see all recent updates here: https://finance.yahoo.com/quote/HOTH/press-releases?p=HOTH
HOTH
HOTH
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Recent RKTO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 12:25:17 PM
- Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for AI, Defense and Space Applications • PR Newswire (US) • 05/28/2026 12:19:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/27/2026 09:30:04 PM
- Rocket One Rebrand Marks Strategic Shift Toward Space AI Chip and Orbital Computing Markets (RKTO) • IH Market News • 05/27/2026 03:49:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 12:33:47 PM
- Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications • PR Newswire (US) • 05/27/2026 12:11:00 PM
- Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform • PR Newswire (US) • 05/26/2026 12:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 08:25:43 PM
- Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH) • IH Market News • 05/19/2026 01:29:23 PM
- AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagn • PR Newswire (US) • 05/19/2026 12:17:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:06:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:07:28 PM
- Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients • PR Newswire (US) • 05/05/2026 08:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:25:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 09:20:01 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/16/2026 09:18:46 PM
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • PR Newswire (US) • 04/14/2026 11:00:00 AM
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • PR Newswire (US) • 04/13/2026 09:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:18:12 PM
- Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering • PR Newswire (US) • 04/02/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/02/2026 05:39:13 PM
- Hoth Therapeutics Announces $2.0 Million Registered Direct Offering • PR Newswire (US) • 04/01/2026 05:52:00 PM
- Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six • PR Newswire (US) • 04/01/2026 12:14:00 PM
- Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology • PR Newswire (US) • 03/31/2026 12:07:00 PM
